Runx1 Orchestrates Sphingolipid Metabolism and Glucocorticoid Resistance in Lymphomagenesis

A. Kilbey,1* A. Terry,1 S. Wotton,1 G. Borland,1 Q. Zhang,2 N. Mackay,1 A. McDonald,1 M. Bell,1 M.J.O. Wakelam,2 E.R. Cameron,1 and J.C. Neil1*

1Molecular Oncology Laboratory, Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow G61 1QH, United Kingdom
2The Babraham Institute, Babraham Research Campus, Cambridge CB22 3AT Cambridgeshire, United Kingdom

ABSTRACT
The three-membered RUNX gene family includes RUNX1, a major mutational target in human leukemias, and displays hallmarks of both tumor suppressors and oncogenes. In mouse models, the Runx genes appear to act as conditional oncogenes, as ectopic expression is growth suppressive in normal cells but drives lymphoma development potently when combined with over-expressed Myc or loss of p53. Clues to underlying mechanisms emerged previously from murine fibroblasts where ectopic expression of any of the Runx genes promotes survival through direct and indirect regulation of key enzymes in sphingolipid metabolism associated with a shift in the “sphingolipid rheostat” from ceramide to sphingosine-1-phosphate (S1P). Testing of this relationship in lymphoma cells was therefore a high priority. We reveal by reduced S1P levels in normal spleen after partial Cre-mediated excision. Furthermore, we show that ectopic expression of Runx1 in lymphoma cells consistently perturbs the sphingolipid rheostat, whereas an essential physiological role for Runx1 is revealed by reduced S1P levels in normal spleen after partial Cre-mediated excision. Furthermore, we show that ectopic Runx1 expression confers increased resistance of lymphoma cells to glucocorticoid-mediated apoptosis, and elucidate the mechanism of cross-talk between glucocorticoid and sphingolipid metabolism through Sgpp1. Dexamethasone potently induces expression of Sgpp1 in T-lymphoma cells and drives cell death which is reduced by partial knockdown of Sgpp1 with shRNA or direct transcriptional repression of Sgpp1 by ectopic Runx1. Together these data show that Runx1 plays a role in regulating the sphingolipid rheostat in normal development and that perturbation of this cell fate regulator contributes to Runx-driven lymphomagenesis.

KEY WORDS: Runx1; Oncogene; Sphingolipid; Glucocorticoid; Survival

RUNX1 (AML1) is one of the most frequently affected genes in human leukemias where it is subject to mutational processes including chromosomal translocation, gene amplification, and point mutation [Osato, 2004; De Braekeleer et al., 2009]. In acute myeloid leukemias, diverse chromosomal breakage and fusion events result in truncation of the RUNX1 gene product and deletion or replacement of the C-terminal transactivation domain with heterologous sequences. Point mutation with apparent loss of function or dominant negative activity is a feature of immature M0 AML [Schnitger et al., 2011] suggesting that RUNX1 may act as a tumor suppressor in this lineage and that the oncogenic fusions operate primarily by a dominant negative mechanism [De Braekeleer et al., 2009]. A tumor suppressor role for Runx1 in myeloid leukemia is also suggested by mouse models where Runx1 deletion is induced, for example, in Flt3-ITD expressing mice [Mead et al., 2013]. However, the notion that RUNX1 is simply a suppressor whose loss of functions confers an automatic growth advantage is challenged by more recent observations that human leukemia cells bearing the common RUNX1-ETO fusion cannot tolerate loss of the remaining wild-type RUNX1 allele [Ben-Ami et al., 2013]. Moreover, although the frequent TEL-RUNX1 fusion in childhood B-ALL is often complemented by loss of the wild-type TEL allele, the unaffected RUNX1 allele is generally intact and is in fact more likely to show copy number gain [Niini et al., 2000]. Early evidence from mouse models showed that all three members of the Runx family can act as targets for transcriptional activation in...
retrovirus-induced lymphomas [Stewart et al., 1997, 2002; Wotton et al., 2002]. Moreover, transgenic over-expression leads to predisposition to lymphoma and is strongly synergistic with other oncogenes (Myc, Myb, Pim1) or loss of p53 tumor suppressor function [Vaillant et al., 1999; Blyth et al., 2001, 2006; Shimizu et al., 2013; Huser et al., 2014]. Although oncogenic activity has been most extensively documented for Runx2, ectopic expression of Runx1 has been shown to collaborate strongly with Myc in T and B-cell lymphomagenesis [Blyth et al., 2009]. Although a small proportion of primary human T-cell acute lymphoblastic leukemias (ALL) carry point mutations in RUNX1 [Grossmann et al., 2011], evidence for an oncogenic role for this gene in childhood B-ALL is suggested by the high expression of RUNX1 [Niini et al., 2000] and high level amplification in a poor prognosis subset [Robinson et al., 2003]. These findings reinforce the hypothesis that the Runx gene family can operate as tumor suppressors or as oncogenes depending on the context in which misregulation occurs.

Clues to the contextual factors that influence the outcome of Runx gain or loss have come from studies in mouse and human fibroblasts where integrity of the p53 pathway determines the response to ectopic Runx expression. Normal primary fibroblasts undergo senescence-like growth arrest in response to ectopic Runx expression, while cells in which the p53 pathway is disabled instead display enhanced survival and oncogenicity [Wotton et al., 2004; Kilbey et al., 2007; Wolyniec et al., 2009]. Moreover, ectopic Runx expression in immortalized Ink4a/Arf null fibroblasts revealed a novel link between oncogenic transcription factors and sphingolipid metabolism [Wotton et al., 2008]. Several enzymes involved in sphingolipid metabolism (Sgpp1, Ugcg, Siat9) were identified as direct Runx targets and regulated in a manner consistent with elevated Sphingosine-1-phosphate (S1P) and reduced ceramide levels, which were also confirmed at the biochemical level [Wotton et al., 2008; Kilbey et al., 2010].

Bioactive lipids mediate many essential roles in normal development and disease. S1P is among the best characterized and is recognized as a regulator of key processes in cancer development including survival, proliferation, and angiogenesis [Takabe et al., 2003]. The precursors of S1P, sphingosine, and ceramide are mediators of cell growth arrest and apoptosis [Zhang et al., 1991; Olivera and Spiegel, 1993; Cuvillier et al., 1996]. Regulation of the balance between these interconvertible lipids forms the basis of the sphingolipid rheostat and the means by which ceramide, sphingosine, and S1P control cell growth and survival in response to environmental and cellular cues. Multiple enzymes control the rheostat and the biochemical processes that generate or degrade its key components [Van Brocklyn and Williams, 2012]. However, despite the wealth of literature on the biology and biochemistry of these processes, links between sphingolipid signaling and cancer gene function, have emerged only recently [Kilbey et al., 2010; Hefferman-Stroud et al., 2012; Burns et al., 2013; Kajiwara et al., 2014]. The evidence of Runx regulation of sphingolipid metabolism in fibroblast survival stimulated our interest in its relevance to lymphomagenesis where there is strong evidence for an oncogenic role. We examined cell lines from p53 null and Eμ-Myc lymphomas where ectopic Runx expression has been shown to collaborate strongly in oncogenesis [Blyth et al., 2001, 2009]. Our results demonstrate a consistent role for Runx1 in control of sphingolipid metabolism in lymphomas as well as in normal development. Moreover, we show that Runx1 regulates glucocorticoid sensitivity in lymphoma cells and identify an established direct target gene, Sgpp1, as an integrator of sphingolipid metabolism and responses to glucocorticoids.

MATERIALS AND METHODS

GENERATION OF TRANSGENIC MICE AND CELL LINES
MxLoxP mice (Mx1CreR Runx1t/0) were created as previously described [Borland et al., 2016]. Mx1Cre positive and negative offspring were treated at seven weeks of age with six injections of 600 μg polyinosinic polycytidylic acid (pIpC), or an equivalent volume of PBS, on alternate days and sacrificed for tissue samples two days after the final pIpC treatment.

Tumor-prone Runx1-floxed mice carrying the EμMyc transgene and heterozygous for p53 loss (Mx1CreR Runx1t/0EμMyc+/p53+/−) were created by crossing Mx1CreR Runx1t/0p53−/−/ mice with Runx1t/0EμMyc+/− mice as previously described [Borland et al., 2016]. Offspring were sacrificed at onset of tumor symptoms and cells from splenic tumors placed into culture to establish cell lines.

Animal protocols used in this work were evaluated and approved by the University of Glasgow Ethics and Welfare Committee and were carried out under Home Office License (approval granted September 2012, license number PPL 60/4408) as governed by the Animal Scientific Procedures Act, 1986 and EU Directive 2010.

CELL CULTURE AND TRANSFECTIONS
Cell lines were established from p53−/− thymic lymphomas or EμMyc splenic lymphomas as previously described [Borland et al., 2016]. Transfections were carried out using Superfect Transfection Reagent (Qiagen, Crawley, UK) according to the manufacturer’s instructions. Conditions for transfection have been previously described (21). The 3s cell line was derived from an Mx1CreR Runx1t/0EμMyc+/p53−/− tumor treated with and without 10U/ml IFNγ (R&D systems) for 8 h to excise Runx1. For growth analyses cells were plated at 5 × 104/ml (T cell lymphoma) or 2.5 × 105/ml (B cell lymphoma) in a 12-well plate in triplicate. Live/dead cell counts were carried out using a hemocytometer and Trypan blue as a vital indicator.

PCR GENOTYPING PROTOCOLS AND PRIMERS
Tissue DNA samples were prepared using the Nucleon Genomic DNA Extraction Kit. Runx1 primers for WT, floxed and deleted alleles, and PCR cycling conditions are as described in Chen et al. [2009]. The PCR products were resolved on a 2.0% TAE agarose gel. Control DNAs includes Balb/c kidney (WT Runx1) and Mx1Cre Runx1t/0 spleen (non-excision floxed Runx1, excised Runx1).

QUANTITATIVE REAL-TIME PCR
Runx1-expressing and control lymphocytes were plated in triplicate on 6 well plates at 5 × 106/well in the presence and absence of 1.0 μM dexamethasone for 6 h. RNA extraction and cDNA preparation were performed as described (21). For quantitative real-time PCR, 12.5 ng aliquots of cDNA were amplified in triplicate using primers for murine endogenous control Hprt or primers for murine Sgpp1, Siat9, Nr3c1,
**Runx1** (Qiagen QuantiTect Primer Assays) or *Ucg1* (779F 5' ttgctcagcatctggagaatta 3' and 861R 5' acttgagtagccgtaaacctc 3'). Relative quantification was carried out and calibrated to vector control samples (18).

**Lentivirus Production and Gene Knockdown**
SMARTvector 2.0 lentiviral shGAPDH and shNC non-coding control particles were purchased from Thermo Scientific (2 × 10⁸ particles/ml). shGAPDH lentiviral particles were included as a positive control for transduction efficiency. Virus supernatants were thawed on the day of transfection and centrifuged onto retroenclin-coated plates at 3220 g for 1 h at 4°C (4 × 10⁵ particles/1.5 ml/well). Supernatants were aspirated from the plates and replaced with fresh supernatant (2 × 10⁵ particles/well) and spun as before. The 10⁵ cells were added in an equal volume per well and incubated for 7 h with 8 µg/ml polybrene. The medium was replaced with fresh medium overnight and then removed. A second infection with 2 × 10⁵ virus particles in an equal volume of fresh medium containing 8 µg/ml polybrene was performed for a further 7 h before the cells were dissociated from the retroenclin and incubated in fresh medium. After 40 h, the medium was replaced with media containing 2 µg/ml puromycin to allow for selection of virally transduced cells. For qRT-PCR and viability counts, puromycin-resistant cells were plated as described in the presence and absence of 1.0 µM dexamethasone.

**Mass Spectrometry: Ceramide and S1P Extraction and Analysis from Cells**
Ceramide and S1P extraction was performed with a modified Folch approach. Briefly, cells from pellets or pulverized tissues were washed twice with cold PBS and re-suspended in 1.5 ml methanol. After addition of 50 ng C17-ceramide and 15 ng C17-S1P as internal standards, 1.5 ml of 0.88% NaCl and 3 ml chloroform were added, the mixture vortexed for 20 s and sonicated for 2 min. Then the sample was centrifuged at 10000 g at 4°C for 15 mins. The lower phase was collected. The upper phase was re-extracted with 3 ml synthetic lower phase (mix chloroform/methanol/0.88% NaCl at 2:5:1 solvent mixture). A total of 7 µl were injected onto a Gemini C8 2.0 × 150 mm column (Phenomenex) for LC/MS/MS analysis of ceramide and quantification of both Q1 and Q3 mass ions. Orbitrap mass analyzer was operated as SIM scan mode with mass range: m/z 510–740, mass resolution: 240 k at m/z 400. Ion trap mass analyzer was operated as dependent scan in CID mode at normal scan speed.

**Mass Spectrometry: S1P Extraction and Analysis from Cell Culture Media**
A total of 800 µl cell culture media, 200 µl 0.88% NaCl, and 2 ml n-butanol were mixed in pre-cleaned 1.5 ml Eppendorf tubes, with 15 ng C17-S1P as internal standard. After vortexing for 20 s at room temperature and sonication in an ice-cold water bath for 3 min, the tubes were centrifuged at 15000 g 4°C for 10 min collecting the upper organic phase. The lower phase was re-extracted with 2 ml n-butanol and the organic extractions combined. The lipid extract was dried under vacuum at room temperature with SpeedVac (Thermo), re-dissolved in 60 µl chloroform/methanol/water 2:5:1 (v/v/v) solvent mixture. A total of 7 µl were injected onto a Gemini−NX−3u C18 2.0 × 150 mm column (Phenomenex) for LC-MS/MS analysis of S1P with Shimadzu Prominence HPLC system hyphenated with AB Sciex 4000 QTRAP mass spectrometer. The S1P separation was carried out with a binary gradient elution at flow rate of 0.25 ml/min with column oven set at 25°C. Mobile phase A: 5% acetonitrile with 1% formic acid and 5 mM ammonium formate; Mobile phase B: 95% acetonitrile with 1% formic acid and 5 mM ammonium formate. The gradient was run from 10% B to 100% B in 10 min. A total of 4000 QTRAP mass spectrometer source/gas parameters: curtain gas: 25; collision gas: high; ionspray voltage: −4500; temperature: 550; ion source gas 1: 30; ion source gas 2: 45; interface heater: on. The following Compound Parameters were used for Multiple Reaction Monitoring (MRM) analysis of each molecular species of S1P. Both Q1 and Q3 mass were set up at unit resolution (Table I).

**Western Blotting and Antibodies**
Preparation of whole cell protein extracts was performed as described previously (21). Samples equivalent to 30 µg of protein (Bio-Rad protein

| TABLE I. Compound Parameters for Multiple Reaction Monitoring |
|-------------------------------------------------------------|
| **Compound** | **Q1 mass (Da)** | **Q3 mass (Da)** | **Declustering potential (DP)** | **Entrance potential (EP)** | **Collision energy (CE)** | **Collision cell exit potential (CXP)** |
|---------------|-----------------|-----------------|-------------------------------|-----------------------------|--------------------------|--------------------------------------|
| C16-S1P       | 350.2           | 78.9            | −90                           | −10                         | −48                      | −5                                   |
| C17-S1P       | 364.2           | 78.9            | −90                           | −10                         | −48                      | −5                                   |
| C18:1-S1P     | 376.2           | 78.9            | −95                           | −8                          | −62                      | −5                                   |
| C18-S1P       | 378.2           | 78.9            | −95                           | −8                          | −62                      | −5                                   |
| C20-S1P       | 406.3           | 78.9            | −95                           | −8                          | −62                      | −5                                   |

methanol/acetonitrile/water/ethylamine solvent gradient based on the polarity of head group. High resolution (240 k at m/z 400) accurate mass (with mass accuracy < 5 ppm) and tandem MS (CID fragmentation) were used for molecular species identification and quantification and further confirmed by reference to appropriate lipids standards. Orbitrap Elite mass spectrometer operation conditions: for ceramide analysis, heated ESI Source in negative ESI mode, heater temperature: 325°C, sheath gas flow rate (arb): 45, aux gas flow rate (arb): 10, sweep gas flow rate (arb): 0, Ion spray voltage: 3.0 kV, capillary temperature: 375°C, S-Lens RF level: 70%. Orbitrap mass analyzer was operated as SIM scan mode with mass range: m/z 510–740, mass resolution: 240 k at m/z 400. Ion trap mass analyzer was operated as dependent scan in CID mode at normal scan speed.
 assay) were resolved on 8% SDS polyacrylamide gels and transferred to enhanced chemiluminescence nitrocellulose membranes (ECL; Amer-sham, Little Chalfont, UK). The antibodies used were α Runx1 #8229 (Cell Signalling Technologies) and α actin sc1616 (Santa Cruz).

STATISTICAL ANALYSIS
Graphs were generated with Excel as mean values and error bars relate to standard deviations. All statistical comparisons were performed using the Student’s t test. Unless stated a significance value = <0.05 is denoted by (‘) and of= <0.01 by (“’).

RESULTS

Runx1 PROMOTES S1P RELEASE FROM LYMPHOMA CELLS
We previously reported that ectopic Runx1 depletes intracellular long chain ceramides and opposes ceramide-induced apoptosis in murine fibroblasts [Kilbey et al., 2010]. To determine whether the sphingolipid rheostat is similarly perturbed in a context where Runx1 has established in vivo oncogenic function [Blyth et al., 2001; Shimizu et al., 2013], we introduced Runx1 into two independently derived p53-null T cell lymphoma lines (Fig. 1A). Vector-driven expression led to increased levels of Runx1 protein at 4.3- and 4.5-fold over the endogenous levels in p/m97 and p53/184 cells, respectively (Fig. 1B). Mass spectrometric analysis of ceramide/S1P revealed modest but consistent reductions in the levels of the most abundantly expressed long chain intracellular ceramides (16.0, 24.1, and 24.0-Cer) in the presence of ectopic Runx1 (Fig. 1C—solid bars P= <0.01). The remaining ceramides (14.0, 16.1, 18.0, 20.0, 22.1, 24.2-Cer; Fig. 1C—hashed bars) were detected at much lower levels but a significant reduction was preserved when these were included in the total (P= <0.01). A more dramatic effect was observed on extracellular C18-S1P which was induced three to fivefold in the presence of ectopic Runx1 (Fig. 1D). The level of induction was further stimulated by serum (FCS) to activate sphingosine kinase and the conversion of sphingosine to S1P. Indeed by 15 min, serum-induced levels of C18-S1P in the presence of ectopic Runx1 (pink bar) exceeded the sum of ectopic Runx1 (red bar) or FCS (gray bar) alone suggesting that ectopic Runx1 and FCS have additive effects in T lymphoma cells and that absolute levels of Runx1 modulate C18-S1P production in vitro.

ENFORCED DELETION OF Runx1 IMPAIRS S1P RELEASE IN VIVO
To determine whether Runx1 plays an essential physiological role in sphingolipid metabolism in vivo we attempted to delete Runx1 in otherwise genetically normal Runx1+/−Mx1Cre+ conditional knockout mice. A previously validated direct PCR assay was used to measure the proportion of excised to non-excised allele in the tissue [Borland et al., 2016]. As reported, most normal mouse tissues resist enforced deletion of Runx1 [Tober et al., 2013], suggesting that this gene plays an essential maintenance role in many mature cell types. Nevertheless, we were able to achieve partial Runx1 ablation in spleen tissues from 60-day-old Runx1+/−Mx1Cre+ transgenic animals where pIpC induction of Cre recombinase led to Runx1 excision rates of ~50–55%. Background excision in Mx1Cre− mice treated with PBS alone was in the order of 40% presumably due to endogenous interferon activity (Fig. 2A). Runx1 transcript levels as measured by q−RT-PCR closely paralleled DNA excision rates in Mx1Cre+ spleens (pale green vs. dark green bars) and were significantly different from control Runx1+/− mice lacking Mx1Cre that showed no response to pIpC treatment (Fig. 2B; gray vs. black bars). Despite these substantial excision rates, Runx1-excised mice showed surprisingly little perturbation in spleen cell populations [Borland et al., 2016]. Parallel tissue samples were processed for biochemical analysis of C18-S1P by mass spectrometry and revealed a strong correlation between loss of Runx1 and C18-S1P in vivo (Fig. 2C). Splenic tissue levels of C18-S1P were moderately reduced by background excision alone (gray bars vs. pale green bars), but significant depletion was observed in the presence of pIpC (black bars vs. dark green bars). To control for non-specific effects of the Cre recombinase spleen tissue samples were prepared from Runx1−/−Mx1Cre− and Runx1−/−Mx1Cre− transgenic mice treated with and without pIpC as described previously. In this case, no significant differences in C18-S1P were recorded between the different experimental groups (data not shown), suggesting that loss of Runx1 was responsible for the reduced levels of C18-S1P in pIpC-treated Runx1+/−Mx1Cre+ mice.
of these, response to dexamethasone in double positive murine thymocytes enzyme expression to promote apoptosis was previously reported in survival mediated by Runx1. Modulation of pro- and anti-apoptotic protection against dexamethasone-induced death is due to increased this cell background (Fig. 3B). Together these data suggest that light of the modest growth inhibition observed with ectopic Runx1 in exposure (Fig. 3A). The protective effect was even more striking in asone that increased markedly from 48 h after dexamethasone observed to provide a sustained protective effect against dexamethasone-induced growth inhibition in murine lymphoma treatment [Bhadri et al., 2012]. Using trypan blue exclusion as a surrogate for viability, ectopic Runx1 was lacking the Mx1Cre gene to control for PBS and pIpC treatment (black and gray bars, respectively). The data are means ± SD where n = 9 representing three technical replicates of each biological replicate (3). A significant reduction in Runx1 expression was observed between Mx1Cre+/Mx1Cre− mice indicating background excision (gray vs. light green bar; P = <0.05). Inclusion of pIpC to excise Runx1 generated a further reduction (black vs. green bar; P = <0.01). (C) Remaining splenic tissues were pulverized and analyzed by HPLC mass spectrometry for C18-S1P. Data are expressed relative to 1 mg of pulverized spleen tissue and represent means ± SD of spleens of three mice for each set of conditions.

Runx1 protects lymphoma cells against dexamethasone-induced apoptosis

We previously reported that each of the three Runx genes can oppose dexamethasone-induced growth inhibition in murine fibroblasts, at least in part by down-regulation of the glucocorticoid receptor gene, Nr3c1 [Wotton et al., 2008]. We tested this observation further in lymphoid cells where dexamethasone induces apoptosis rather than growth stasis and glucocorticoids feature as important therapeutic agents in lymphoma treatment [Bhadri et al., 2012]. Using trypan blue exclusion as a surrogate for viability, ectopic Runx1 was observed to provide a sustained protective effect against dexamethasone that increased markedly from 48 h after dexamethasone exposure (Fig. 3A). The protective effect was even more striking in light of the modest growth inhibition observed with ectopic Runx1 in this cell background (Fig. 3B). Together these data suggest that protection against dexamethasone-induced death is due to increased survival mediated by Runx1. Modulation of pro- and anti-apoptotic enzyme expression to promote apoptosis was previously reported in response to dexamethasone in double positive murine thymocytes [Bianchini et al., 2006]. Of these, Sgpp1 and Ugcg were also identified as direct transcriptional targets of Runx1 in murine fibroblasts, whereas the glucocorticoid receptor Nr3c1 was identified as an indirect target [Wotton et al., 2008; Kilbey et al., 2010]. To determine whether Runx1 opposed dexamethasone-mediated gene expression to promote cell survival we examined transcription of Runx1, Sgpp1, Ugcg, and Nr3c1 by qt-RT-PCR in the presence and absence of dexamethasone and ectopic Runx1. As shown in Figure 3C, endogenous Runx1 was repressed by dexamethasone as previously reported, but the pattern was reversed in the presence of ectopic Runx1. In contrast, Sgpp1 expression was dramatically opposed by ectopic Runx1 in dexamethasone-treated p/m97 cells whereas Nr3c1 expression was not. Indeed, as previously reported in murine fibroblasts, Nr3c1 was slightly downregulated by ectopic Runx1 but was upregulated by dexamethasone in both the presence and absence of ectopic Runx1 [Wotton et al., 2008]. Ugcg expression was refractory to dexamethasone treatment in p53-null thymic lymphoma cells but was induced by Runx1. This finding contrasts with double positive murine thymocytes where Ugcg was reportedly repressed by dexamethasone [Bianchini et al., 2006] but was consistent with the effects of ectopic Runx1 on Ugcg transcription in murine fibroblasts [Wotton et al., 2008; Kilbey et al., 2010]. Together the data support a mechanism whereby the opposition of Sgpp1 transcription and the overexpression of Ugcg might contribute to Runx1-induced survival in the presence of dexamethasone in thymic lymphoma cell lines.
Runx1 EXCISION PROMOTES DEXAMETHASONE-INDUCED APOPTOSIS AND Sgpp1 TRANSCRIPTION

To further explore the relationship between Runx1 and Sgpp1 in dexamethasone-induced apoptosis, we examined Runx1<sup>fl/fl</sup>/Mx1Cre<sup>+</sup> B cell lymphoma lines established from a mouse model heterozygous for p53 loss and expressing c-Myc in the B cell compartment (E<sub>m</sub>-Myc). We exploited interferon β induction of Mx1Cre to mediate in vitro excision of Runx1 and derived a pair of clonally identical daughter cell lines that express low but readily detectable levels of full length Runx1 (Runx1Fl) or the deleted non-functional variant (ΔRunx1Fl—Fig. 4A) and asked whether loss of Runx1 promotes dexamethasone-induced apoptosis and Sgpp1 transcription. Enforced deletion of endogenous Runx1 significantly increased cell death in response to 1.0 μM dexamethasone (Fig. 4B). Moreover, enforced deletion of Runx1 increased expression of Sgpp1 in ΔRunx1Fl cells (black vs. green bars) and this was further increased in the presence of dexamethasone (hashed black vs. green bars) (Fig. 4C). Parallel cell lines derived from Runx1<sup>wt/wt</sup>/Mx1Cre<sup>+</sup>/p53<sup>+</sup>/E<sub>m</sub>-Myc lymphomas were refractory to interferon β with respect to Sgpp1 and Runx1 expression (Borland et al., 2016) thereby excluding a non-specific effect of the Mx1Cre recombinase as a causative factor for the increase in Sgpp1 expression following Runx1 excision. To determine which functional domains of Runx1 are required to suppress Sgpp1 induction in the presence of dexamethasone, we introduced a panel of Runx1 mutants (Fig. 4D) into ΔRunx1Fl cells which essentially lack Runx1 expression. qT-RT-PCR analysis revealed that Runx1 repression of Sgpp1 was dependent on intact DNA binding and heterodimerization domains (Fig. 4D), indicating that Runx1 directly opposes dexamethasone-induced transcription of Sgpp1.

Sgpp1 KNOCKDOWN REDUCES DEXAMETHASONE-INDUCED CELL DEATH

To investigate the role of Sgpp1 as a direct mediator of glucocorticoid-mediated apoptosis we used a short hairpin (sh) RNA to knock down expression of Sgpp1 in p/m97 thymic lymphoma cells which displayed the most dramatic induction of Sgpp1 in response to dexamethasone (Fig. 3C—black bar vs. hashed black bar). Retroviral transduction of Sgpp1 shRNA viral supernatants reduced dexamethasone-induced expression of Sgpp1 by ~40% compared to the non-coding (NC) shRNA control sequences (Fig. 5A). Stably transduced cells were then cultured in the presence and absence of dexamethasone and cell death measured by trypan blue exclusion. After 36 hr, dexamethasone-induced death was reduced by ~20% in cells receiving Sgpp1 shRNA compared to the NC shRNA control sequence (Fig. 5B). Together these data indicate that Sgpp1 induction is at least partially responsible for death of lymphoma cells mediated by glucocorticoid signaling. Insights gained from this data regarding the interplay between dexamethasone and Runx1 for the regulation of sphingolipid metabolism and cell survival are illustrated in the model shown in Figure 5C.

DISCUSSION

Previous studies in murine fibroblasts identified three sphingolipid metabolism enzymes as direct transcriptional targets of the three
members of the Runx gene family [Wotton et al., 2008; Kilbey et al., 2010]. Moreover, the pronounced pro-survival effects of ectopic Runx expression in this context were associated with depletion of intracellular ceramide levels suggesting a shift in the sphingolipid rheostat in favor of pro-survival S1P [Kilbey et al., 2010]. We have now extended these studies to the lymphoid system where ectopic Runx expression has been shown to be potently oncogenic in combination with other cancer gene lesions including p53 loss and Myc over-expression [Vaillant et al., 1999; Blyth et al., 2001, 2006; Shimizu et al., 2013]. In thymic lymphoma cells Runx1 expression consistently regulates sphingolipid metabolism to favor S1P production with concomitant reduction in long chain ceramides. As we found, no positive effect of Runx1 over-expression in this cell background, these results strongly reinforce previous evidence for enhanced survival as a key mechanism in Runx oncogenesis [Blyth et al., 2006]. However, we have shown that partial deletion of Runx1 in vivo results in a significant and specific reduction in tissue S1P levels, revealing a fundamental physiological role for Runx regulation of sphingolipid metabolism in normal hematopoiesis. The production and distribution of S1P in spleen is known to be tightly regulated [Ramos-Perez et al., 2015] and the importance of Runx1 expression for maintenance of S1P levels described here is likely to be critical for regulation of the immune system.

The regulation of sphingolipid metabolism by the Runx genes is a multigenic phenomenon involving both direct and indirect gene regulation and entails a series of incremental changes in individual genes that combine to achieve significant metabolic shifts [Wotton et al., 2008; Kilbey et al., 2010]. However, this study highlights an additional need to measure transcriptomic changes under stress if the consequences of Runx modulation for sphingolipid metabolism are to be fully understood. In particular, ectopic Runx1 significantly impaired the massive induction of Sgpp1 in T-lymphoma cells in response to dexamethasone, but had no effect on basal expression of the gene in these cells. Similarly, although Sgpp1 was up-regulated in response to deletion of Runx1 in B-lymphoma cells, the differential was more marked in the presence of dexamethasone. Replacement with ectopic Runx1 reversed this effect, but not when the DNA or Cbfβ cofactor binding functions were disabled, indicating that suppression most likely operates through the previously mapped binding site in the Sgpp1 promoter [Kilbey et al., 2010].

Dexamethasone is a synthetic glucocorticoid that induces ceramide and sphingosine to promote apoptosis in mouse thymocytes in a manner that mimics the normal process of T cell selection in the thymus [Cifone et al., 1999; Lepine et al., 2004]. Previous studies in primary mouse thymocytes identified changes in Runx1, Nr3c1, Ugcg, and Sgpp1 as early consequences of dexamethasone
treatment compatible with ceramide-induced apoptosis [Bianchini et al., 2006]. Our studies in lymphoma cells partially recapitulate these findings, and indicate a causal chain in which down-regulation of Runx1 is proximal to the other changes and reversed by ectopic expression. Moreover, we have identified positive regulation of Ugcg and repression of Sgpp1 as consistent Runx1 functions. An effector role for Sgpp1 in the depletion of S1P and concomitant dexamethasone-induced death is further supported by shRNA knock down of Sgpp1 which, although far from complete, showed a significant sparing effect.

The importance of S1P for survival and drug resistance has been well documented in hematological malignancies but is more commonly attributed to deregulation of Sphk1 or Ugcg rather than to reduced levels of Sgpp1 [Marfe et al., 2011; Casson et al., 2013]. However, the fundamental importance of Sgpp1 is underlined by the neonatal lethality of gene deletion in mice [Allende et al., 2013] and the effects of modulating expression on cell growth and survival in response to cellular stress. For example, depletion of Sgpp1 promotes ER stress-induced autophagy in eukaryotic cell lines [Lepine et al., 2011] and thermo tolerance in yeast [Mao et al., 1999], whereas ectopic expression of Sgpp1 promotes apoptosis and accumulation of intracellular ceramide in NIH3T3 and HEK293 fibroblasts [Le Stunff et al., 2002]. The relevance of SGPP1 in other cancer types is suggested by its down-regulation in therapy-resistant ovarian and prostate cancers [Helleman et al., 2006; Huang et al., 2013].

The observation that ectopic Runx1 suppresses glucocorticoid-induced death and that deletion of endogenous Runx1 has the opposite effect also helps to elucidate the oncogenic consequences of Runx over-expression in lymphoid cells [Stewart et al., 1997, 2002; Wotton et al., 2002]. Moreover, glucocorticoids comprise key components of multi-drug regimens for the treatment of acute lymphoid malignancies, where resistance is common but the underlying in vivo mechanisms poorly understood [Bhadri et al., 2012]. Our results predict that perturbations in expression of RUNX family members in human leukemia will be relevant to cell survival and therapy resistance. In support of this hypothesis, human t(8;21) leukemias that carry only a single functional RUNX1 allele are unique among AMLs in their sensitivity to glucocorticoids [Miyoshi et al., 1997]. Moreover, relapsing t(12;21) leukemias harboring the TEL-RUNX1 fusion display mutually exclusive gains of extra wild-type RUNX1 on chromosome 21 and losses of the glucocorticoid receptor Nr3c1. In light of these and our observations reported here it will therefore be interesting to test the synergistic potential of glucocorticoids and...
hiders of RUNX-CBFβ functions [Illeendula et al., 2016] or their key downstream targets in sphingolipid metabolism [Edmonds et al., 2011] in the growing number of cancers where the RUNX genes are implicated as oncogenic drivers [Ito et al., 2015].

ACKNOWLEDGMENTS

This work was supported by a joint programme grant from Cancer Research UK (grant number A1951) and Bloodwise (grant number 13046). Lipidomic analyses were performed at the Babraham Institute and supported by grants from Cancer Research UK and the BBSRC (MJOW). We thank Nancy Speck (University of Pennsylvania) for kind provision of Runx1fl/fl mice.

REFERENCES

Allende ML, Sipe LM, Tuyetmoga G, Wilson-Henjum KL, Chen W, Proia RL. 2013. Sphingosine-1-phosphate phosphatase 1 regulates keratinocyte differentiation and epidermal homeostasis. J Biol Chem 288:18381–18391.

Ben-Ami O, Friedman D, Leshkowitz D, Goldenberg D, Orlovsky K, Pencovich N, Lotozen T, Tanay A, Groner Y. 2013. Addiction of CD95 and in (16) acute myeloid leukemia to native RUNX1. Cell Rep 4:1131–1143.

Bhadri VA, Trahair TN, Lock RB. 2012. Glucocorticoid resistance in paediatric acute lymphoblastic leukemia. J Paediatr Child Health 48:634–640.

Bianchini R, Nocentini G, Kraus LT, Fettuciani K, Coaccioli S, Ronchetti S, Riccardi C. 2006. Modulation of pro- and antiapoptotic molecules in double-positive (CD4+CD8+) thymocytes following dexamethasone treatment. J Pharmacol Exp Ther 319:887–897.

Blyth K, Slater N, Hanlon L, Bell M, Mackay N, Stewart M, Neil JC, Cameron ER. 2009. Runx1 promotes B-cell survival and lymphoma development. Blood Cells Mol Dis 43:12–19.

Blyth K, Terry A, Mackay N, Vaillant F, Bell M, Cameron ER, Neil JC, Stewart M. 2001. Runx2: A novel oncogenic effector revealed by in vivo complementation and retroviral tagging. Oncogene 20:295–302.

Blyth K, Vaillant F, Hanlon L, Mackay N, Bell M, Jenkins A, Neil JC, Cameron ER. 2006. Runx2 and MYC collaborate in lymphoma development by suppressing apoptotic and growth arrest pathways in vivo. Cancer Res 66:2195–2201.

Borland G, Kilbey A, Hay J, Gilroy K, Terry A, Mackay N, Bell M, McDonald A, Mills K, Cameron E, Neil JC. 2016. Addiction to Runx1 is partially attenuated by loss of p53 in the Emicro-Myc lymphoma model. Oncotarget 7:22973–22987.

Burns TA, Sunathra M, Signorelli P, Choi Y, Yang X, Wang Y, Villani M, Bhalla K, Zhou D, Libertz C. 2013. Sphingomyelin syntheses 1 activity is regulated by the BCR-ABL oncogene. J Lipid Res 54:794–805.

Casson L, Howell L, Mathews LA, Ferrer M, Southall N, Guha R, Keller JM, Thomas C, Siskind LJ, Beverly LJ. 2013. Inhibition of ceramide metabolism sensitizes human leukemia cells to inhibition of BCL2-like proteins. PLoS ONE 8:e54526.

Chen MJ, Yokomizo T, Dzierzak E, Speck NA, Neil JC. 2007. Runx2 disruption promotes immortalization and confers resistance to oncogene-induced senescence in primary murine fibroblasts. Cancer Res 67:11263–11271.

E. 2009. Modulation of pro- and antiapoptotic molecules in double-positive (CD4+CD8+) thymocytes following dexamethasone treatment. J Pharmacol Exp Ther 319:887–897.

Edmonds Y, Milstein S, Spiegel S. 2011. Development of small-molecule inhibitors of sphingosine-1-phosphate signaling. Pharmacol Ther 132:352–360.

Grossmann V, Kern W, Harbisch A, Alpermann T, Jeromin S, Schnittger S, Haferlach C, Haferlach T, Kohlmann A. 2011. Prognostic relevance of RUNX1 mutations in T-cell acute lymphoblastic leukemia. Haematologica 96:1874–1877.

Heffernan-Stroud LA, Helke KL, Jenkins RM, De Costa AM, Hanunn YA, Obeid LM. 2012. Defining a role for sphingosine kinase 1 in p53-dependent tumors. Oncogene 31:1166–1175.

Hellemann J, Jansen MP, Span PN, van Staveren IL, Massuger LF, Meijer-van Gelder ME, Sweep FC, Ewing PC, van der Burg ME, Stoter G, Nooter K, Berns EM. 2006. Molecular profiling of platinum resistant ovarian cancer. Int J Cancer 118:1963–1971.

Huang X, Taeb S, Jahangiri S, Emmenegger U, Tran E, Bruce J, Mesi C, Obepe EA, Vesprini D, Wong CS, Bristow R, Liu FY, Liu SK. 2013. MRNA-95 mediates radiosensitivity in tumors by targeting the sphingolipid phosphatase SGPP1. Cancer Res 73:6972–6986.

Huter CA, Gilroy K, de Ridder J, Kilbey A, Borland G, Mackay N, Jenkins A, Bell M, Herzyk P, van der Weyden L, Adams DJ, Rust AG, Cameron E, Neil JC. 2014. Insertional mutagenesis and deep profiling reveals gene hierarchies and a Myc/p53-dependent bottleneck in lymphogenesis. PLoS Genet 10:e1004167.

Illeendula A, Gilmore J, Grembecka J, Tirumula VS, Boulton A, Kunitamaddi A, Schmidt C, Wang L, Pulikkan JA, Zong H, Park M, Kuscu C, Picklin A, Zhou Y, Gao Y, Mishra L, Adil M, Castilla LH, Rajewski RA, Janes KA, Guzman ML, Bonifer C, Bushwell BH. 2016. Small molecule inhibitor of CBFbeta-RUNX binding for RUNX transcription factor driven cancers. EBioMedicine 8:117–131.

Ito Y, Bae SC, Chuang LS. 2015. The RUNX family: Developmental regulators in cancer. Nat Rev Cancer 15:81–95.

Kajiwara K, Yamada T, Bamba T, Fujukasumi I, Imae F, Okada M, Onyama C. 2014. c-Src-induced activation of ceramide metabolism impairs membrane microdomains and promotes malignant progression by facilitating the translocation of c-Src to focal adhesions. Biochem J 458:81–93.

Kilbey A, Blyth K, Wotton S, Terry A, Jenkins A, Bell M, Hanlon L, Cameron ER, Neil JC. 2007. Runx2 disruption promotes immortalization and confers resistance to oncogene-induced senescence in primary murine fibroblasts. Cancer Res 67:11263–11271.

Kilbey A, Terry A, Jenkins A, Borland G, Zhang Q, Wakelman MJ, Cameron ER, Neil JC. 2010. Runx2 regulation of sphingolipid metabolism and survival signaling. Cancer Res 70:5860–5869.

Le Stunff H, Galve-Roperh I, Peterson C, Milstein S, Spiegel S. 2002. Sphingosine-1-phosphate phosphohydrolase in regulation of sphingolipid metabolism and apoptosis. J Cell Biol 158:1039–1049.

Lepine S, Allegood JC, Park M, Dent P, Milstein S, Spiegel S. 2011. Sphingosine-1-phosphate phosphohydrolase-1 regulates ER stress-induced autophagy. Cell Death Differ 18:350–361.

Lepine S, Allegood JC, Park M, Dent P, Milstein S, Spiegel S. 2011. Sphingosine-1-phosphate phosphohydrolase-1 regulates ER stress-induced autophagy. Cell Death Differ 18:350–361.

Lepine S, Allegood JC, Park M, Dent P, Milstein S, Spiegel S. 2011. Sphingosine-1-phosphate phosphohydrolase-1 regulates ER stress-induced autophagy. Cell Death Differ 18:350–361.

Lepine S, Allegood JC, Park M, Dent P, Milstein S, Spiegel S. 2011. Sphingosine-1-phosphate phosphohydrolase-1 regulates ER stress-induced autophagy. Cell Death Differ 18:350–361.

Mao C, Saba JD, Obeid LM. 1999. The dihydrosphingosine-1-phosphate 1 phosphatase 1 regulates sphingolipid metabolism and apoptosis. J Cell Biol 158:1039–1049.

Marie G, Di Stefano C, Gambacorta A, Bottone T, Martini V, Abruzzese E, Mologni L, Simonhaldi-Salemi P, de Fabritius P, Gambacorti-Passerini C, Amadori S, Birge RB. 2011. Sphingosine kinase 1 overexpression is regulated by signaling through PI3K-AKT2, and mTOR in imatinib-resistant chronic myeloid leukemia cells. Exp Hematol 39:653–665.

Mead AJ, Kharazi S, Atkinson D, Macaulay I, Pecquet C, Loughran S, Lutteropp M, Woll P, Chowdhury O, Luke S, Buza-Vidas N, Ferry H, Clark SA, De Braekeleer E, Ferec C, De Braekeleer M. 2009. RUNX1 translocations in malignant hemopathies. Anticancer Res 29:1031–1037.

Edmonds Y, Milstein S, Spiegel S. 2011. Development of small-molecule inhibitors of sphingosine-1-phosphate signaling. Pharmacol Ther 132:352–360.
Goardon N, Vyas P, Constantinescu SN, Sitnicka E, Nerlov C, Jacobsen SE. 2013. FLT3-ITDs instruct a myeloid differentiation and transformation bias in lymphomyeloid multipotent progenitors. Cell Rep 3:1766–1776.

Miyoshi H, Ohki M, Nakagawa T, Honma Y. 1997. Glucocorticoids induce apoptosis in acute myeloid leukemia cell lines with a t(8;21) chromosome translocation. Leuk Res 21:45–50.

Niini T, Kanerva J, Vettenranta K, Saarinen-Pihkala UM, Knuutila S. 2000. AML1 gene amplification: A novel finding in childhood acute lymphoblastic leukemia. Haematologica 85:362–366.

Olivera A, Spiegel S. 1993. Sphingosine-1-phosphate as second messenger in cell proliferation induced by PDGF and FCS mitogens. Nature 365:557–560.

Osato M. 2004. Point mutations in the RUNX1/AML1 gene: Another actor in RUNX leukemia. Oncogene 23:4284–4296.

Ramos-Perez WD, Fang V, Escalante-Alcalde D, Cammer M, Schwab SR. 2015. A map of the distribution of sphingosine 1-phosphate in the spleen. Nat Immunol 16:1245–1252.

Robinson HM, Broadfield ZJ, Cheung KL, Harewood L, Harris RL, Jalali GR, Martineau M, Moorman AV, Taylor KE, Richards S, Mitchell C, Harrison CJ. 2003. Amplification of AML1 in acute lymphoblastic leukemia is associated with a poor outcome. Leukemia 17:2249–2250.

Schnittger S, Dicker F, Kern W, Wendland N, Sundermann J, Alpermann T, Haferlach C, Haferlach T. 2011. RUNX1 mutations are frequent in de novo AML with noncomplex karyotype and confer an unfavorable prognosis. Blood 117:2348–2357.

Shimizu K, Yamagata K, Kurokawa M, Mizutani S, Tsunematsu Y, Kitabayashi I. 2013. Roles of AML1/RUNX1 in T-cell malignancy induced by loss of p53. Cancer Sci 104:1033–1038.

Stewart M, MacKay N, Cameron ER, Neil JC. 2002. The common retroviral insertion locus Dsi1 maps 30 kilobases upstream of the P1 promoter of the murine Runx3/Cbfa3/Aml2 gene. J Virol 76:4364–4369.

Stewart M, Terry A, Hu M, O’Hara M, Blyth K, Baxter E, Cameron E, Onions DE, Neil JC. 1997. Proviral insertions induce the expression of bone-specific isoforms of PEBP2alphaA (CBFA1): Evidence for a new myc collaborating oncogene. Proc Natl Acad Sci USA 94:8646–8651.

Takabe K, Paugh SW, Milstien S, Spiegel S. 2008. “Inside–out” signaling of sphingosine-1-phosphate: Therapeutic targets. Pharmacol Rev 60:181–195.

Tober J, Yzaguirre AD, Piwarzyk E, Speck NA. 2013. Distinct temporal requirements for Runx1 in hematopoietic progenitors and stem cells. Development 140:3765–3776.

Vallant F, Blyth K, Terry A, Bell M, Cameron ER, Neil J, Stewart M. 1999. A full-length Chfa1 gene product perturbs T-cell development and promotes lymphomagenesis in synergy with myc. Oncogene 18:7124–7134.

Van Brocklyn JR, Williams JB. 2012. The control of the balance between ceramide and sphingosine-1-phosphate by sphingosine kinase: Oxidative stress and the seesaw of cell survival and death. Comp Biochem Physiol B Biochem Mol Biol 163:26–36.

Wolyniec K, Wotton S, Kilbey A, Jenkins A, Terry A, Peters G, Stocking C, Cameron E, Neil JC. 2009. RUNX1 and its fusion oncoprotein derivative, RUNX1-ETO, induce senescence-like growth arrest independently of replicative stress. Oncogene 28:2502–2512.

Wotton S, Stewart M, Blyth K, Vaillant F, Kilbey A, Neil JC, Cameron ER. 2002. Proviral insertion indicates a dominant oncogenic role for Runx1/AML1 in T-cell lymphoma. Cancer Res 62:7181–7185.

Wotton S, Terry A, Kilbey A, Jenkins A, Hezrky P, Cameron E, Neil JC. 2008. Gene array analysis reveals a common Runx transcriptional programme controlling cell adhesion and survival. Oncogene 27:5856–5866.

Wotton SF, Blyth K, Kilbey A, Jenkins A, Terry A, Bernardin-Fried F, Friedman AD, Baxter EW, Neil JC, Cameron ER. 2004. RUNX1 transformation of primary embryonic fibroblasts is revealed in the absence of p53. Oncogene 23:5476–5486.

Zhang H, Desai NN, Olivera A, Seki T, Brooker G, Spiegel S. 1991. Sphingosine-1-phosphate, a novel lipid, involved in cellular proliferation. J Cell Biol 114:155–167.